Enoxaparin sodium biosimilar - Biocad

Drug Profile

Enoxaparin sodium biosimilar - Biocad

Alternative Names: BCD 080; Enoxaparin biosimilar - Biocad

Latest Information Update: 19 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biocad
  • Class Antithrombotics; Low molecular weight heparins
  • Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Deep vein thrombosis; Venous thromboembolism

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Jan 2015 Phase-III clinical trials in Deep vein thrombosis in Russia (SC) (NCT02368314)
  • 01 Jan 2015 Phase-III clinical trials in Venous thromboembolism in Russia (SC) (Biocad pipeline, July 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top